Dr. Terence Flotte — Dean of the School of Medicine, UMass Medical School, a pediatrician, and a Gene Therapy investigator who has run multiple clinical trials — explains that because trials in rare disease are designed to get to FDA approval as quickly as possible, the initial number and criteria for patients is likely to be narrow — to increase chances of success … which will benefit the greater good.